This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s).
Prescribing Information was available at the meeting and is available in the links below.
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com.

0 UK head start slim banner 1440x130px.png

Unpacking the psychological impact of headaches and migraines

From Head Start's Annual Meeting, June 2024

Dr Giorgio Lambru discusses psychological comorbidities

Dr Giorgio Lambru discusses psychological comorbidities including insomnia, anxiety, and depression in migraine patients, emphasising the importance of a holistic biopsychosocial approach to address patients’ unmet needs in migraine therapy.01

Dr Lambru highlights findings from the UNITE study, which suggest that patients treated with fremanezumab for migraines might also experience improvement in their depression symptoms.0203

 

Abbreviations

CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.

Discover more about Head Start's Annual Meeting

Prescribing Information  

Prescribing Information: AJOVY® (fremanezumab)
Prescribing Information: Amitriptyline

Upcoming Head Start Events

Sign up to hear about upcoming webinars or events

Sign up

More On Demand Recordings

Additional materials from Head Start events and meetings

Discover more
Back to Head Start Hub

  

References

  1. Back to contents.

    Dudeney J, Sharpe L, McDonald S, Menzies RE, McGuire B. Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis. Headache. 2022;62(4):405-419. doi:10.1111/head.14260

  2. Back to contents.

    Lipton RB, et al. Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.

  3. Back to contents.

    Lipton RB, et al. Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: results of the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.

Date of preparation: February 2025
Reference: D: MIG-GB-00463 (V1.0) / T: MIG-GB-00464 (V1.0) / M: MIG-GB-00465 (V1.0)

This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.

Teva Logo.png

Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX  
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.

Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events